<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820493</url>
  </required_header>
  <id_info>
    <org_study_id>EVeA Study</org_study_id>
    <nct_id>NCT02820493</nct_id>
  </id_info>
  <brief_title>Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF</brief_title>
  <official_title>Effectiveness of Vedolizumab Therapy in Inducing Clinical Remission in CD Patients Naïve to Anti-TNF and Its Capability to Halt Disease Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universita degli Studi di Genova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universita degli Studi di Genova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-cytokine antibodies, such as Infliximab (an anti TNF alfa chimeric antibody) and&#xD;
      Adalimumab (an anti TNF alfa humanize antibody), have been developed and used in clinical&#xD;
      practice for the treatment of patients with Crohn disease (CD). Unfortunately, their efficacy&#xD;
      is limited. Based on these concepts, a new drug has been developed for IBD treatment.&#xD;
      Vedolizumab (VDZ) is able to recognize the α4β7 heterodimer, and selectively blocks gut&#xD;
      lymphocyte trafficking.&#xD;
&#xD;
      The hypothesis of this study is that VDZ therapy may be to halt CD disease progression during&#xD;
      time and modifying its natural history, using Lemann Index.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients who will enter in the study will be follow-up at weeks 2-6-14-22-30-38-46 or&#xD;
      before in case of relapse. A relapse will be defined by an Harvey Bradshaw Index ≥ 5 for 2&#xD;
      consecutive weeks. The following data are to be recorded:&#xD;
&#xD;
        1. Physical examination&#xD;
&#xD;
        2. Adverse Event Review&#xD;
&#xD;
        3. Weight in Kg&#xD;
&#xD;
        4. Full blood count&#xD;
&#xD;
        5. Biochemical series including serum iron, serum ferritin, C reactive protein (PCR), ESR&#xD;
           (eritrosedimatation rate)&#xD;
&#xD;
        6. Fecal Calprotectin&#xD;
&#xD;
        7. VDZ fecal loos&#xD;
&#xD;
        8. VDZ trough levels and antidrug antibodies&#xD;
&#xD;
        9. Current treatments&#xD;
&#xD;
      The last visit will be performed at week 54. The following data are to be recorded:&#xD;
&#xD;
        1. Physical examination&#xD;
&#xD;
        2. Adverse Event Review&#xD;
&#xD;
        3. Weight in Kg&#xD;
&#xD;
        4. Full blood count&#xD;
&#xD;
        5. Biochemical series including serum iron, serum ferritin, C reactive protein (PCR), ESR&#xD;
           (eritrosedimatation rate)&#xD;
&#xD;
        6. Fecal Calprotectin&#xD;
&#xD;
        7. VDZ fecal loos&#xD;
&#xD;
        8. VDZ trough levels and antidrug antibodies&#xD;
&#xD;
        9. Current treatments&#xD;
&#xD;
       10. Routine lower and upper gastrointestinal endoscopy and magnetic resonance imaging or&#xD;
           computed tomography of the small bowel&#xD;
&#xD;
       11. SES-CD&#xD;
&#xD;
       12. Lemann Index&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Internal problems&#xD;
  </why_stopped>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Harvey Bradshaw index</measure>
    <time_frame>Week 0-14</time_frame>
    <description>Primary responders will defined as by a decrease of Harvey Bradshaw Index at week 14 of 3 point from the Harvey Bradshaw Index calculate at week 0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lèmann Index</measure>
    <time_frame>Week 0 and Week 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VDZ trough levels</measure>
    <time_frame>Week 0-2-6-14-22-30-38-46-54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-drug antibodies</measure>
    <time_frame>Week 0-2-6-14-22-30-38-46-54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fecal VDZ loss</measure>
    <time_frame>Week 0-2-6-14-22-30-38-46-54</time_frame>
    <description>The investigators will evaluated the VDZ quantity (microgram) that a patients with mucosal ulcers could loss in patients feces.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>single arm study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vedolizumab 300 mg iv at week 0, week 2 and week 6, than every 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vedolizumab</intervention_name>
    <arm_group_label>single arm study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have given written informed consent to participate&#xD;
&#xD;
          -  Be aged between 18 and 80&#xD;
&#xD;
          -  Have a moderate/severe CD defined by an HBI &gt;7 CD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous treatment with anti-TNF drugs,&#xD;
&#xD;
          -  concomitant use of immune-modulator drugs for CD (azathioprine/6-mercaptopurine,&#xD;
             methotrexate)&#xD;
&#xD;
          -  ulcerative colitis (UC) or inflammatory bowel disease undetermined (IBD-U) diagnosis&#xD;
&#xD;
          -  symptomatic obstructive disease&#xD;
&#xD;
          -  bowel resection within the past 6 months&#xD;
&#xD;
          -  ileostomy&#xD;
&#xD;
          -  extensive small bowel resection (as determined by the investigator) or a short bowel&#xD;
             syndrome&#xD;
&#xD;
          -  patients who are currently receiving total parenteral nutrition&#xD;
&#xD;
          -  history of cancer in the past 5 years&#xD;
&#xD;
          -  pregnancy known at the study inclusion&#xD;
&#xD;
          -  positive Clostridium difficile stool assay&#xD;
&#xD;
          -  Listeria, human immunodeficiency virus, central nervous system demyelinating disease,&#xD;
             untreated tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universita degli Studi di Genova</investigator_affiliation>
    <investigator_full_name>Giorgia Bodini</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vedolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

